Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser - Trial NCT00523588
Access comprehensive clinical trial information for NCT00523588 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Pennsylvania and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Pennsylvania
Timeline & Enrollment
Phase 2
Mar 01, 2007
Jan 01, 2010
Primary Outcome
Comparison of laser treated CLE skin lesions with a non-treated control CLE lesion of the same patient evaluated by the CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) and the M-CLASI (Modified CLASI).
Summary
The purpose of using the 595 nm Vbeam Perfecta™ flashlamp-excited, pulsed dye laser in this
 study is to help improve study patients' skin disease. Cutaneous lupus erythematosus (CLE)
 often presents with disfiguring vascular lesions which are frequently difficult to treat with
 the available therapeutic measures, such as photoprotection, topical steroids, and
 antimalarials. Laser therapy provides an alternative treatment option for CLE patients.
 Although there has been documented experience with laser treatment in CLE patients, no study
 comparing treated lesions to the natural course of the disease has been conducted.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT00523588
Non-Device Trial